Mitchell Chan's Insider Trades & SAST Disclosures
Mitchell Chan's most recent trade in Avalo Therapeutics Inc was a trade of 3,167 Restricted Stock Units done . Disclosure was reported to the exchange on March 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mitchell Chan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Mitchell Chan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Mitchell Chan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Regenxbio Inc | Mitchell Chan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 62,547 | 62,547 | - | - | Stock Options (Right to buy) | |
| Pactiv Evergreen Inc | Mitchell J. Chandra | Chief Legal Officer & Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 94,456 | 274,925 | - | 0 | Common Stock | |
| Pactiv Evergreen Inc | J. Mitchell Chandra | Chief Legal Officer & Sec. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.32 per share. | 16 Dec 2024 | 72,481 | 202,444 | - | 17.3 | 1,255,371 | Common Stock |
| Pactiv Evergreen Inc | Mitchell J. Chandra | Chief Legal Officer & Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 3,556 | 180,469 | - | 0 | Common Stock | |
| Regenxbio Inc | Mitchell Chan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2024 | 289,362 | 289,362 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Mitchell Chan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2024 | 58,869 | 58,869 (0%) | 0% | 0 | Common Stock | |
| Avalo Therapeutics Inc | Mitchell Chan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mitchell Chan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | |
| Pactiv Evergreen Inc | Chandra J. Mitchell | Chief Legal Officer & Sec. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.63 per share. | 24 Jun 2024 | 18,104 | 176,913 | - | 11.6 | 210,550 | Common Stock |
| Pactiv Evergreen Inc | Chandra J. Mitchell | Chief Legal Officer & Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 38,077 | 195,017 | - | 0 | Common Stock | |
| Pactiv Evergreen Inc | Chandra J. Mitchell | Chief Legal Officer & Sec. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.26 per share. | 02 Mar 2024 | 13,583 | 156,940 | - | 13.3 | 180,111 | Common Stock |
| Pactiv Evergreen Inc | Chandra J. Mitchell | Chief Legal Officer & Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2024 | 2,110 | 170,523 | - | 0 | Common Stock | |
| Avalo Therapeutics Inc | Mitchell Chan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2023 | 3,334 | 3,334 | - | - | Stock Option (Right to Buy) | |
| Pactiv Evergreen Inc | Chandra J. Mitchell | Chief Legal Officer & Sec. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.35 per share. | 24 Jun 2023 | 17,710 | 168,413 | - | 7.4 | 130,169 | Common Stock |
| Pactiv Evergreen Inc | Chandra J. Mitchell | Chief Legal Officer & Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 48,727 | 186,745 | - | 0 | Common Stock | |
| Pactiv Evergreen Inc | Chandra J. Mitchell | Chief Legal Officer & Sec. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.30 per share. | 02 Mar 2023 | 6,235 | 137,396 | - | 11.3 | 70,456 | Common Stock |
| Pactiv Evergreen Inc | Chandra J. Mitchell | Chief Legal Officer & Sec. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.77 per share. | 24 Jun 2022 | 12,352 | 143,009 | - | 9.8 | 120,679 | Common Stock |
| Avalo Therapeutics Inc | Mitchell Chan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Pactiv Evergreen Inc | Chandra J. Mitchell | Chief Legal Officer & Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 48,196 | 155,361 | - | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges